Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Tourette Syndrome

Part of Movement Disorders

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Tourette Syndrome

28 trials tracked for Tourette Syndrome: 8 in phase 3 or 4 and 3 with published results. The most-cited published study has 192 citations.

28Trials tracked

8Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 4 4 Phase 3 4 Phase 2 10 Other / NA 10

Phase 3 A Randomized, Placebo-controlled, Tourette Syndrome Study. Completed · 192 cited
Phase 3 A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS) Completed · 40 cited
Phase 3 Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Completed · 39 cited
Phase 4 Guanfacine in Children With Tic Disorders Completed
Phase 4 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Completed
Phase 4 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed

Show 22 more trials

Phase 4 Comparison of Keppra and Clonidine in the Treatment of Tics Completed
Phase 3 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Completed
Phase 2 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Completed
Phase 2 Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed
Phase 2 Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents Completed
Phase 2 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Completed
Phase 2 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria Completed
Phase 2 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Completed
Phase 2 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed
Phase 2 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed
Phase 2 Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome Completed
Phase 2 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Completed
N/A Tourette Syndrome Deep Brain Stimulation Completed
N/A Median Nerve Stimulation Pilot Completed
N/A Combined CBIT and rTMS to Improve Tourette's Syndrome Completed
N/A Brain Stimulation for the Treatment of Tourette Syndrome Completed
N/A Response Inhibition in Tourette Syndrome Completed
N/A Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome Completed
N/A Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics Completed
N/A Repetitive Transcranial Magnetic Stimulation to Reduce Tics Completed
N/A Transcranial Magnetic Stimulation for Children With Tourette's Syndrome Completed
N/A Open-label MNS for Tourette Syndrome Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Tourette Syndrome: what the trials found

Topiramate demonstrated a statistically significant reduction in Total Tic Score at Day 70 ⁵. Other pharmacological interventions, including Ondansetron, D-serine, Levetiracetam, and Valbenazine, were evaluated but did not reach statistical significance in their primary tic severity outcomes [1, 3, 4, 11].

Multiple trials evaluating TEV-50717 at various doses and time points (8 to 12 weeks) showed no statistically significant difference compared to placebo regarding the Yale Global Tic Severity Scale (YGTSS) Total Tic Score or Clinical Global Impression scores [6, 7]. Similarly, NBI-98854 did not show statistically significant improvements in YGTSS Total Tic Scores or Clinical Global Impression scores at 6 or 8 weeks [13, 14].

Recent results — preliminary, needs further review

Ecopipam showed a statistically significant reduction in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) at Week 12 (p=0.011) ⁹.
AZD5123 demonstrated a statistically significant difference in Total Tic Severity Score during crossover analysis (p=0.0087) ¹⁶.

For the clinician treating this condition

Topiramate is supported by evidence showing a statistically significant reduction in total tic scores at 70 days ⁵.
Several agents, including Valbenazine and NBI-98854, were tested for tic severity but did not reach statistical significance in primary outcomes [11, 13, 14].
TEV-50717 failed to show statistically significant improvement over placebo in multiple trials [6, 7].

AI synthesis of 3 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.